Big Data in the Assessment of Pediatric Medication Safety

Abstract

Big data (BD) in pediatric medication safety research provides many opportunities to improve the safety and health of children. The number of pediatric medication and device trials has increased in part because of the past 20 years of US legislation requiring and incentivizing study of the effects of medical products in children (Food and Drug Administration Modernization Act of 1997, Pediatric Rule in 1998, Best Pharmaceuticals for Children Act of 2002, and Pediatric Research Equity Act of 2003).There are some limitations of traditional approaches to studying medication safety in children. Randomized clinical trials within the regulatory context may not enroll patients who are representative of the general pediatric population, provide the power to detect rare safety signals, or provide long-term safety data. BD sources may have these capabilities. In recent years, medical records have become digitized, and cell phones and personal devices have proliferated. In this process, the field of biomedical science has progressively used BD from those records coupled with other data sources, both digital and traditional. Additionally, large distributed databases that include pediatric-specific outcome variables are available. A workshop entitled "Advancing the Development of Pediatric Therapeutics: Application of 'Big Data' to Pediatric Safety Studies" held September 18 to 19, 2017, in Silver Spring, Maryland, formed the basis of many of the ideas outlined in this article, which are intended to identify key examples, critical issues, and future directions in this early phase of an anticipated dramatic change in the availability and use of BD.

International Analysis of Electronic Health Records of Children and Youth Hospitalized With COVID-19 Infection in 6 Countries

“…For example, EHR data have been applied to more efficiently assess medication safety in children and youth or to test at scale potential associations between risk factors and pediatric conditions. 5 , 6 These data are particularly conducive to the study of small populations or rare events that can be difficult to capture in smaller data sets. 7 , 8 Other key benefits of EHR data include the ability to ascertain clinical trajectories and to facilitate multinational studies by combining data across health care systems.…”

Off‐label drug use in neonates and infants in Spain: A five‐year observational study

“…In addition to the specific regulation that encourages paediatric drug development, big data (i.e., patient registries, real‐world data and digital health) will bring an expanded knowledge about paediatric medication use, which will definitely help improving the safety of this population group 41 …”

International consensus validation of the POPI tool (Pediatrics: Omission of Prescriptions and Inappropriate prescriptions) to identify inappropriate prescribing in pediatrics

“…There is a strong demand for increased pediatric medication safety [ 26 – 28 ]. POPI, validated bu 20 experts–both pharmacists and physicians recruited across the world, it the first international tool created to satisfy this demand, by the detection of pediatric inappropriate prescription and omission of prescription.…”